1. Home
  2. TBPH vs MYE Comparison

TBPH vs MYE Comparison

Compare TBPH & MYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TBPH
  • MYE
  • Stock Information
  • Founded
  • TBPH 2013
  • MYE 1933
  • Country
  • TBPH United States
  • MYE United States
  • Employees
  • TBPH N/A
  • MYE N/A
  • Industry
  • TBPH Biotechnology: Pharmaceutical Preparations
  • MYE Auto Parts:O.E.M.
  • Sector
  • TBPH Health Care
  • MYE Consumer Discretionary
  • Exchange
  • TBPH Nasdaq
  • MYE Nasdaq
  • Market Cap
  • TBPH 485.8M
  • MYE 414.7M
  • IPO Year
  • TBPH N/A
  • MYE N/A
  • Fundamental
  • Price
  • TBPH $9.59
  • MYE $11.38
  • Analyst Decision
  • TBPH Buy
  • MYE Hold
  • Analyst Count
  • TBPH 4
  • MYE 1
  • Target Price
  • TBPH $13.75
  • MYE N/A
  • AVG Volume (30 Days)
  • TBPH 217.1K
  • MYE 816.7K
  • Earning Date
  • TBPH 11-12-2024
  • MYE 11-04-2024
  • Dividend Yield
  • TBPH N/A
  • MYE 4.74%
  • EPS Growth
  • TBPH N/A
  • MYE N/A
  • EPS
  • TBPH N/A
  • MYE 0.42
  • Revenue
  • TBPH $63,192,000.00
  • MYE $823,482,000.00
  • Revenue This Year
  • TBPH $11.41
  • MYE $3.80
  • Revenue Next Year
  • TBPH $37.36
  • MYE $3.27
  • P/E Ratio
  • TBPH N/A
  • MYE $27.34
  • Revenue Growth
  • TBPH 15.93
  • MYE N/A
  • 52 Week Low
  • TBPH $7.44
  • MYE $10.35
  • 52 Week High
  • TBPH $11.71
  • MYE $23.63
  • Technical
  • Relative Strength Index (RSI)
  • TBPH 50.13
  • MYE 42.98
  • Support Level
  • TBPH $9.62
  • MYE $11.81
  • Resistance Level
  • TBPH $10.08
  • MYE $12.44
  • Average True Range (ATR)
  • TBPH 0.31
  • MYE 0.48
  • MACD
  • TBPH -0.06
  • MYE -0.03
  • Stochastic Oscillator
  • TBPH 25.00
  • MYE 8.21

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to better meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

About MYE Myers Industries Inc.

Myers Industries Inc designs, manufactures, and markets a variety of plastic, metal, and rubber products, including a broad selection of plastic reusable containers, pallets, small parts bins, bulk shipping containers, storage and organization products, OEM parts, custom plastic products, consumer fuel containers and tanks for water, fuel and waste handling. It operates through the following segments: The Material Handling segment, which designs manufactures, and markets a variety of plastic and metal products. The Distribution segment offers tools, equipment, and supplies used for tire, wheel, and under-vehicle service on passenger, heavy truck, and off-road vehicles. It generates the majority of its revenue from the Material Handling segment.

Share on Social Networks: